CLAIMS

1. Use of ~~A method of treating cancer in a mammal comprising administering to a mammal in need thereof~~ a Toll- Like Receptor (TLR) agonist for the manufacture of a medicament for the treatment of ~~wherein the~~ cancer in a mammal, wherein the cancer is present in a tissue that expresses ~~TLR~~ TLR5, the TLR agonist comprising the amino acid sequence of SEQ ID NO: 8.

2. Use of a TLR agonist in the manufacture of a medicament for ~~A method of~~ reducing cancer recurrence in a mammal ~~comprising administering to a mammal in need thereof a TLR agonist~~, wherein the cancer is present in a tissue that expresses ~~TLR~~ TLR5, the TLR agonist comprising the amino acid sequence of SEQ ID NO: 8.

3. The ~~method~~use of claim 2, wherein the cancer recurrence is selected from the group consisting of a metastasis and tumor regrowth.

~~4. The method of any one of claims 1-3, wherein the TLR agonist is flagellin.~~

~~5~~4. The ~~method~~use of any one of the preceding claims, wherein the cancer does not express TLR.

~~6. The method of any one of the preceding claims, wherein the TLR is TLR5.~~

~~7~~5. The ~~method~~use of any one of the preceding claims, wherein the tissue is selected from the group consisting of liver, lung, bladder, and intestinal.

~~8. The method of any one of the preceding claims, wherein in the cancer is a tumor.~~

~~9~~6. The ~~method~~use of ~~claim 8~~ any one of the preceding claims, wherein the cancer is selected from the group consisting of melanoma, colon, breast, prostate, and a hematological malignancy.

~~10~~7. The ~~method~~use of any one of the preceding claims, wherein the cancer is a tumor.

~~11~~8. The ~~method~~use of claim ~~9~~6, wherein the hematological malignancy is lymphoma.

~~12~~9. The ~~method~~use of any one of the preceding claims, wherein the agonist is ~~administered~~ used as a monotherapy.

~~13~~10. The ~~method~~use of any one of the preceding claims, wherein the mammal is not receiving a combination cancer therapy.

~~14~~11. The ~~method~~use of claim ~~13~~10, wherein the mammal is not receiving chemotherapy or radiation therapy.

~~15~~12. The ~~method~~use of any one of the preceding claims, wherein the mammal has sufficient innate immunity.

~~16~~13. The ~~method~~use of claim 12~~15~~, wherein the sufficient immunity level is equivalent to the level required for eligibility for a first or subsequent round of chemotherapy.

~~17~~14. The ~~method~~use of claim ~~15~~12, wherein the mammal has a white blood cell count that is within the range of clinically normal.

~~18. The method of any one of the preceding claims, wherein the TLR agonist is administered to the mammal before, after, or concurrent with removal of a tumor.~~

~~19~~15. The use of any one of the preceding claims wherein the treatment further comprises ~~A method of treating cancer in a mammal, comprising administering to a mammal in need thereof~~ a FAS agonist ~~and a TLR agonist~~.

~~20. The method of claim 19, wherein the TLR agonist is flagellin.~~

~~21~~16. The ~~method~~ use of claim ~~19~~15, wherein the FAS agonist is a FAS agonist antibody.

~~22. The method of claim 19, wherein the cancer is metastatic.~~

~~23. The method of claim 22, wherein the cancer is a tumor.~~

~~24. The method of claim 22, wherein the metastatic cancer does not express a TLR, and wherein the cancer has metastasized to an invaded tissue that expresses TLR.~~

~~25. The method of claim 24, wherein the invaded tissue is selected from the group consisting of liver, bladder, lung, and intestinal.~~

~~26. A method of protecting liver tissue in a mammal from the effects of a liver toxicity comprising administering to a mammal in need thereof a Toll-Like Receptor agonist.~~

~~27. The method of claim 26, wherein the toxicity is selected from the group consisting of a FAS ligand, a FAS agonistic antibody, TNF , acetaminophen, alcohol, a viral infection of the liver, and a chemotherapeutic agent.~~

~~28. A method of treating a Salmonella infection in a mammal, comprising administering to a mammal in need thereof a TLR agonist.~~

~~29. The method of claim 28, wherein the TLR agonist is flagellin.~~

~~30. The method of claim 28, wherein the Salmonella is Salmonella typhimurium.~~

~~31. The method of claim 28, wherein the infection is present in liver tissue.~~